In particular, individuals with TERT promoter mutations demonstrated a more favorable prognosis compared to those with wildtype TERT promoter, specifically in grade II or III oligodendroglioma, 1p/19q-codeleted patients, and IDH-mutant cases (13, 14). This evidence concerns the gene TERT and oligodendroglioma.